Transcode Therapeutics, Inc.
RNAZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829635
No open-market purchases or sales by Transcode Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $208.1K in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Transcode Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 9
- −10 vs. Q1 2025
- Shares held
- 30.4K
- −2.11M (−98.6%) vs. Q1 2025
- Total value
- $237.0K
- −$823.1K (−77.6%) vs. Q1 2025
- New holders
- 1
- 1 more added
- Sold out
- 11
- 7 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RNAZ on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 8 | $208.1K |
| Q1 2026 | 8 | $265.7K |
| Q4 2025 | 6 | $26.4K |
| Q3 2025 | 8 | $155.0K |
| Q2 2025 | 9 | $237.0K |
| Q1 2025 | 19 | $1.06M |
| Q4 2024 | 5 | $33.4K |
| Q3 2024 | 10 | $185.8K |
| Q2 2024 | 15 | $263.0K |
| Q1 2024 | 7 | $284.1K |
| Q4 2023 | 13 | $105.4K |
| Q3 2023 | 11 | $281.6K |
| Q2 2023 | 5 | $476.6K |
| Q1 2023 | 11 | $88.6K |
| Q4 2022 | 18 | $222.5K |
| Q3 2022 | 13 | $2.27M |
| Q2 2022 | 13 | $2.67M |
| Q1 2022 | 13 | $3.14M |
| Q4 2021 | 16 | $5.98M |
| Q3 2021 | 17 | $7.28M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Transcode Therapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Goldman Sachs Group Inc | 28,042 | $218.7K | 0.00% | +28,042 | New |
| UBS Group AG | 1,432 | $11.2K | 0.00% | −262,497−99.5% | Reduced |
| South State Corp. | 482 | $3.76K | 0.00% | −17,528−97.3% | Reduced |
| Tower Research Capital LLC (TRC) | 402 | $3.14K | 0.00% | −1,125−73.7% | Reduced |
| SBI Securities Co., Ltd. | 10 | $78 | 0.00% | −364−97.3% | Reduced |
| Bank of America Corp | 8 | $63 | 0.00% | +2+33.3% | Added |
| Advisor Group Holdings, Inc. | 3 | $23 | 0.00% | −97−97.0% | Reduced |
| FMR LLC | 3 | $23 | 0.00% | −22−88.0% | Reduced |
| Royal Bank of Canada | 16 | $0 | 0.00% | −234−93.6% | Reduced |
| Anson Funds Management LP | 0 | $0 | 0.00% | −1,462,112−100.0% | Sold out |
| Sabby Management, LLC | 0 | $0 | 0.00% | −229,052−100.0% | Sold out |
| Warberg Asset Management LLC | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| Corsair Capital Management, L.P. | 0 | $0 | 0.00% | −40,000−100.0% | Sold out |
| Commonwealth Equity Services, LLC | 0 | $0 | 0.00% | −21,674−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −22,323−100.0% | Sold out |
| Ground Swell Capital, LLC | 0 | $0 | 0.00% | −14,363−100.0% | Sold out |
| Marex Group plc | 0 | $0 | 0.00% | −12,678−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −5,000−100.0% | Sold out |
| Danske Bank A/S | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| BlackRock, Inc. | 0 | $0 | 0.00% | −1−100.0% | Sold out |